好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Regulatory T cells Modulate B-cell Calcium Fluctuation
Multiple Sclerosis
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-076

To investigate the interaction of B cells and Treg cells on a single-cell level.


Recent evidence suggests that an impaired peripheral B-cell tolerance accounts for elevated frequencies of pathogenic B cells in patients with multiple sclerosis (MS).  This effect might be conferred by a hampered control of T-cell dependent and/or T-cell independent B-cell activity through regulatory T cells (Treg). At present, little is known as to whether B cells are direct targets of Treg cells and how suppression of B-cell effector function is achieved. Possible mechanisms could be the modulation of immunoglobulin production, antigen presentation and cytokine secretion. Regulation of molecular calcium (Ca2+) influx is a key mechanism utilized by Treg cells to confer suppression in conventional CD4+ T cells (Tconv) as we could previously show.either Treg cells or Tconv.

 We isolated B cells, Treg cells and Tconv from peripheral blood samples of healthy donors and used an in-house live cell imaging setup for visualization. We established an experimental paradigm allowing single-cell analysis of Ca2+ signaling patterns and associated downstream signaling events in classified lymphocytes. With this method we were able to assess Ca2+ fluctuations in B cells and B-cell subsets stimulated with CD40 and IgM alone or in co-culture with either Treg cells or Tconv.

Results: We found distinct patterns of Ca2+ signaling in CD27+ memory and CD27- naïve B cells. We could further demonstrate that Ca2+ signals of B cells are reduced when co-cultured with Treg cells but not when co-cultured with Tconv.


We provide new information on Ca2+ signaling behaviour in B cells and B-cell subsets. We conclude that immediate inhibition of Ca2+ influx is likely to be a major mechanism of Treg cells to confer B-cell suppression.


Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Mirjam Korporal-Kuhnke, MD Dr. Korporal-Kuhnke has nothing to disclose.
Sven O. Jarius, MD (University of Heidelberg) Dr. Jarius has nothing to disclose.
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology) The institution of Dr. Wildemann has received research support from Roche. The institution of Dr. Wildemann has received research support from Novartis. The institution of Dr. Wildemann has received research support from Argenx. Dr. Wildemann has received personal compensation in the range of $500-$4,999 for serving as a Conference participant with Neuraxpharm. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Soeaker with Instand.